FORM PTO	-144	<u> </u>									
4				;	30727.0013.0	'NO. 3121			IAL N 518,5	- • •	
A E	PATE	INTS AND OTHER IT IMATION DISCLOS	TEMS FOR A	PPLICANT'S	APPLICANT:						
<i>y</i> •	% .			15	METABASIS THERAPEUTICS, INC. FILING DATE: GROUP:						
1011 1 200		ise several sheets i	necessary)	-+	March 5, 1999	9		161			
TRADE!	0										
U.S. PATENT DOCUMENTS											
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		IAME	0	ASS_		SUB LASS		LING
the	Ad	3,018,302	01.23.62						<u> </u>	"	ATE
	AB	5,157,027	10/20 92	Biller, et al.							
	AC	5,658,889	8/19/97	Gruber, et a	ı. /						· · · · · · · · · · · · · · · · · · ·
•										- L	
			POREIGN	PATENT DO	CUMENTS	 -		<u>·</u>			
EXAMINER INITIAL		POCH INFORMATION						SI	JB	TRANS	LATION
WN	AD	O 002 062 A	30.05.78	X	INTRY	4	ASS	a	ves	YES	NO
	AE	0 072 531 A	23,62.83	EP (Abstract		H					
	AF	0 158 057 A	16.10.85	EP (Abstract					-		
	AG	0 180 276	28.12.88	EP (Abstract		H					
	AH	0 261/283		EP					_		
	Al	0 161 955 A	22.09.86	EP							
	AJ		21.11.85	EPO							
	AK	0 338 372 A	25.10.89	EPO			V	-			
			07.02.90	EPO				\neq			
2	AL		22.04.92	EPO			_	+	\mathcal{A}		
1/1/	AM	/	30.06.70 /	CH		_					
<u> </u>	AN	16 93 219 _A	17.09.70	DE (Abstract)	A						
		<u>U</u>	Gue	All Cle	Wes			<u> </u>			
EXAMINER:	1/	m		DATE	CONSIDÈRED:	19	/ε	·~			
EXAMINER line through communicati	CHALLO	ial if reference is co on if not in conformations	ensidered, wance and no	hether or not cital considered. In	ation is in confor	man his fo	ce w	ith M with 1	PEP next	609; Di	aw

			• • •								
FORM	PTO	৮ ৪ব্বর	(**		ATTY. DOC THO. SERIAL HO. 30727.0013.CIP1 09/518,501					
ี้ เมร	t of	Pate	nts and other in	Tems for a	Plicant's	30727.0013.C	IP1	09/	518,5	<u>01</u>	
			mation disclos	urie statem	ent	METABASIS THERAPEUTICS, INC.					
6	Ø E		ès saveral sheets l	inecessary)		Filing Date: March 5, 1999		GR(oup: A		
		1 18 M	É			MEICH S, 1888		101	~? ~~~~~		
	Wil 4			FOREIGH	i patent do	CUMENTS					
FXAMI	क्षेत्रहरू	RADE						Τ.		TRANS	LATION
INITI	AL		DOCUMENT NUMBER				CLASS	CLÁZZ CTÝZZ		XZS NO	
K		AO	35 12 781 A1	10.04.85	DE (and Engles) U.S. Patent	glish language No. 4,952,740)					
	<u> </u>	AP	96/01267 A	18.01.96	wo						
		ACA	97/03679 A	06.02.97	wo						
•		AR	98:09668 A	12.03.98	wo	/.					
		AS	98/39345	11.09.98	WO						
	·	AT	98/39343	11.09.98	wo /						
		AU	98/39344	1.09.98	WO						
								1			
		OTKI	er documents	(Ipcludin	g Author, Til	de, Date, Perti	nent F	`ඔුමුළ	s, etc	2.)	·
of	A	W_	"Patent Abstract (Yamishata Koji;	s of Japan," Nippon So	Vol. 1998, No da Co. 140), 1	o. 1, 30 January 5 September 19	1998 & 97	L JP (09 24	1284 A	
	A	w	DeLombaert, et a Mew Generation (198-5)	al., "N-Phos on of Neutra	phonomethyl	Dipeptides and	Their P	hosp) Inhi	hona bitors	le Prod , <u>J. M</u> e	rugs, <u>d.</u>
			Edmunson, et al. Assignments in the Structure of cis-2	he 4-Pheny	I-1.3.2λ5-diox	aphospharinana	Series	. X-F	av M	olecula	r
Ä-	A	Х	Res. Synop., 5:	22-123 (19	89)						
	A	v	Farquhar, et al., 'fluorouridine: a n (FDUMP)'* J. Me	nembrane-p	ermeating pro	drug of 5-fluoro	in an - -2'-030	2-y][- xyuri	2'∘ded dylic a	oxy-5- acid	
1	+^	' 	-					1			
7	A	Z	Farquhar, et al., '72(3): 324 (1983)) / Diologically	Keversible P	nospnate-Protec	CIIVO GI	roups	3," <u>J. }</u>	<u> narm.</u>	Sci.
		Q.		9/1	cal	25					
EXAMINE Examipe		Vho		11 Y)	DATE	CONSIDERED:	6/1	رير سر		~ <u>-</u> -	
	- C	JIC.	ial if reference is a		othor or and the	ation in in	7/ (<u>ノレ</u>			
line thro	ugh	citatio	ial if reference is co on if not in conform	ance and not	considered. In	auon is in conton clude a copy of th	m ance v is form	vith i\ with	aper Next	DUY; Dr	aw

communication to applicant

• 1									
			TO-1449	~	ATTY. DOG 7 NO. 30727.0013.CIP1	Serial no. 09/518,501			
	_	isi (nts and other items for applicant's Mation disclosure statement	applicant: METABASIS THERA				
) "C	118		se several sheets if necessary)	Filing Date: March 5, 1999	Group: 1614			
	w^	110	E_						
P	A		NI OF THE	IER DOCUMENTS (Including Author, Ti	de, Date, Pertinent l	Pages, etc.)			
	3	MAD	BA	Farquhar, et al., "Synthesis and Biologica oxazaphosphorinan-2-yl)-6-D-arabinosylldioxazaphosphorinan-2-yl)-6-D-arabinosylladenine 5'-Monoph (1985)	adenine and 9-[5'-(2-0 /l]adenine: Potential Ne nosphate," <u>J. Med. Ene</u>	xo-1,3,2- extral Precursors of 9- em. 28: 1358-1361			
			Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-BB Puoro-2'-deoxyuridine 5'-Phosphate," J. Med. Cham. 26: 1153-1158 (1983)						
	•		BC	Freed, et al., "Evidence For Acyloxymethy Deoxyribonucleotides as Extracellular Sol Cultured Cells," <u>Biochem. Pharmac.</u> 38. 3	rces of Active 5'-Deox	5'- syribonucleotides in			
			BD.	Hillers, et al., Analogs of pyrimidinemono (1,4-dihydroxy-2-pentyl)thymine and 1-(1, Soedin 5:678-683 (1978). Chem Abst. v 8	-and polynucleotides. I 3-dihydroxy-2-propyl) L	racil." Khim Geterotski			
		Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters BE Derived from 2'-Deoxy-5-fistorouridine," J. Med. Chem. 27: 440-444 (1984)							
			BF	Kryuchkov, et al, Izv. Akad, Nauk SSSR,	Ser. Khim. 6: 1201-124	48 (1987)			
			₿G	Lok, et al., "Neurotoxicity associated with treatment of chronic hepatitis B virus infect (1984)	adenine arabinoside m	onophosphate in the			
			вн/	Ludeman, et al., "Synthesis and Antitumor Preparation, Kinetic Studies, and Anticand and Similar Compounds Related to the Cy Aldophosphamide," J. Med Chem. 29, 716	er Screening of "Pheny clophosphamide Metal	vi ketophos phamide"			
			BI	Meier, et al., "Cyclic Saligenyl Phosphotre didehydrothymidine (d4T) – A New Pro-Nu Lett. 7: 99-104 (1977)	isters of 2', 3'-Dideoxy- ucleotide Approach," <u>Bi</u>	2', 3'- oorg. Med. Chem.			
$\frac{1}{2}$			BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyc Thiolnosinic Acid," J. Med. Chem. 22: 811-	klic 3', 5'-Phosphates (a -815 (1979)	s Prodrugs of			
			8K	Neidlein, et al., "Mild Preparation of 1-Benz Application to the Synthesis of Cyclic Phos Amides," Meterocycles 35: 1185-1203 (199	zyloxyiminoalkylphospl sphonic Deisters and C	nonia Dichlorides: cyclic Monoester			
			_ 1	HIII NIX II					
ł	EXAM Exam	INER		Danes DIM DATE	CONSIDERED:	02			
	7			tial if reference is considered the					
11	ing t	uton	gh citatio	tial if reference is considered, whether or not cit on if not in conformance and not considered. In applicant	auon is in conformande victude a copy of this form	with MPEP 609; Draw with next			
			W			. 1			

•										
•		M PTO-		•	ATTY, DOC 1 NO. 30727.0013.CIP1	SERIAL NO. 09/518,501				
				ITS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:					
	61	OF !	NFORI	MATION DISCLOSURE STATEMENT	METABASIS THERAPEUTICS, INC.					
	6	1 - vc). Ø./11.	se several sheets if necessary)	FILING DATE:	GROUP:				
/		lma	B. LOS	e several sitests if necessary)	March 5, 1999	1614				
•	ln.	1100	E							
1			S THI	ER DOCUMENTS (Including Author, Ti	tle, Date, Pertinent	Pages, etc.)				
	V	L RAUE M								
	1	. *		Nifant'ev, et al., "1,3,2, - Diazaphodsphori	inanes", <u>Zh. Obshch. K</u>	<u>(him</u> ., Vol. 49, No. 1,				
	1	\mathcal{U}_{-}	.\	1979, Pages 64-74 (and English version a	as translated in corresp	onding English				
	1			Language publication)						
	1 1			Nifantyev, et al., "Synthesis and Structure	of Some Stable Phosp	holane-				
		<u> </u>	BM	Phospholanes," Phos. Sulfur & Silicon 113	3, 1-13 (1996)					
	1	ł								
,	!			Predvoditelev D., et al., "Glycero-2-hydro	xymethylene phosphal	es" Journal of Organic				
!	\vdash	B	N	Chemistry of the USSR (English Translati	or 13:1489-1492 (197	7))				
1				Predvoditeley, D. et al., "Synthesis of ligid	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol					
				alkylene phosphites. V. Cyclic phosphatid	alkylene phosphites. V. Cyclic phosphatidylglycerol and					
			İ	phosphatidylhydroxyhomocholipe" Journa	of Omanic Chemistry	of the LISSP /English				
		В	0	<u>Translation</u> 17:1156-1165 (1981)	i or organic onemistry	or the OSSIN (English				
			_ 1	Shaw & Cundy, "Biological Screens of PM	(EA Prodrugs," Pharm.	Res. 10 (Suppl) S24				
ı		<u> </u>	P	(1993)						
		- 1		Shih, et al., "Preparation and Structures of	f 2-Dimethylamino-4-nl	nenvi-1 3 2-				
		В	Q	dioxaphosphorinane-2-oxides," Bull. Inst.	Chem. Acad. Sh. 41.9	3-16 (1994)				
			1	Starrett, et al., "Synthesis, Oral Bioavailab	ollity Determination, and	Lin Vitro Evaluation of				
I	1		_	Prodrugs of the Antiviral Agent 9-[2-(Phos	phonomethoxy)-ethylja	idenine (PMEA)," <u>J.</u>				
ŀ	-	B	K ,	Med. Chem. 37: 1957-1864 (1994)						
١				Yamanaka, et al., "Metabolic Studies on B	MS-200475 a New An	tiviral Compund				
l	_1	BX	5	Active against Hepatitis B Virus," Antimicro	ob. Agents Chemoth 4	3 190-103 (1909)				
I	-Q	7.	l l	_						
L	* **	<u>∕</u> B	<u>!</u> }	Zon, ét al., "4 Cyclophosphamide Analogu	es," Prog. Med. Chem.	19: 205-246 (1982)				
	•		\iint	11 /1/2/1/1/65						
			M	" GO MI COES	9					
				- 11						

EXAMINER:		T
Examiner)	Dun Mily	DATE CONSIDERED:
EXAMINER: line through cit	Initial if reference is considered, whether or tation if not in conformance and not conside	not citation is in conformance with MPEP 609; Draw ered. Include a copy of this form with next
communication	n to applicant	••

	e plus sign (*) inside this		FB 25 ZIII	7C53 &	Approved and Tredemant and to a collection of Information	the Suph 10/31/300	TO/58/08A (68-00) 12. OMB 0851-0031 IT OF COMMERCE OMB control number	-
	Substitute for form 1448A/PTO				•	mplete If Known)
40		~10	OCH AGISTIAN	A	oplication Number	09/318,501		\$
113	Formation (Dia	Lusure		ling Date	Merch 3, 2000		
\$	tatement b'	y ap	PLICANT		irst Named Inventor	Erlon .?	40_	
·					roup Art Unit	1624	Cu 40	
	(use 88 many	sheets	es necessary)	F	maminer Name	T. McKenzie	Ce	
Sheet	1	of	2		Itomey Docket Number	030727.0013.CIP1	- Silva	×0000 "

•				U.S. PATENT DOCU	iments	
Exeminar Initials*	Cha No.	U.S. Paten	l Cocument Hand Codo [†] (Il targen)	Nome of Patentee or Applicant of Cited Document	Octo of Publication of Cited Document MM-OD-YYYY	Pegga, Ushman, Urca, Witch Robsom Postogae of Reichant Rauma Agrapy
			U Daily			- Distriction of the second of
		CD/				

			Foreign Patent Doc	ument	Name of Pointer or	Date of Publication of	Popo, Column, Linn, White Belong	70
Exember Initials	Cite No. ¹	Office	Number	Kifeel Code? (g*	Applicant of Cited Document	Clied Decument MM-DD-YYYY	Passym or Relovest Figures Appear	
								Į.
						 		╬
		L				 		╁
								+

			non patent literature documents	
Examiner Initiato		Cita No.	includo reme of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the liam (book, magazina, journal, sarie), symposhum, catalog, etc.), date, page(e), volume-lasue numbor(e), publisher, city and/or country where published.	72
/	200	AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
		AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gens Therapy, 5, 1070-1078 (1988).	
		AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3- Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy," Vol. 42, p. 1146-1150 (May 1998).	
V		AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutethione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

Examiner Signature Considered Considered	1/13	<i> </i> 03

*EXAMPLER: Initial if reference considered, whether or not clistion to in conformance with MPEP 609. One line through distion to not in conformance and not considered, truthed copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be cent to the Chief Information Officer, U.S. Petent and Tredsmark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patento, Washington, OC 20231.

EDILIDINICOS SEITERAS

^{*}Unique citation designation number. * See exacted Kinds of U.S. Petent Documents. * Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the raign of the Emparer must precede the certal number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. * Applicant to place a check mark here if English language Translation is effected.

Plasse type a plus sign (+) inside this box 🤜 Under the Peperwark Reduction Act of 1985, no po Substitute for form 1449A/PTO

PTO/SB/08A (08-00)
Approved for 30 through 10/31/2002. CMB 0851-0031
Patent and Tradament Office: U.S. DEPARTMENT OF COMMERCE

A. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERC are required to registral to a collection of information unless it contains a valid CMS control number TRANFUR Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	-		'
Application Number	09/518,501		-
Filing Date	March 5, 1999		Me.
First Named Inventor	Erion	JAA	40
Group Art Unit	1624	CHA	- 0
Examiner Name	T. McKenzie	- 6	Air
Attorney Docket Number	030727.0013.CI	PI	1782

		NON PATENT LITERATURE DOCUMENTS	
Examiner Inflate	Cite No.'	include name of the author (in CAPITAL LETTERS), title of the pricie (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-(ssue number(s), publisher, city end/or country where published.	71
Nu	AE	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of Grapefruit Juice," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	E e
9~	AF	Journaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy," Cancer Research, Vol. 58, p. 4391-4401 (Oct. 1, 1998).	
·		·	
			ᅦ
			\dashv
			1

		1	1
Examiner Qual III	Date	2/13/	03
	Considerate	100	03

*EXAMINER: Initial if reference considered, whether or not clietion is in conformance with MPEP 609. Draw tine through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradament Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,

¹ Unique cristian designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

1					•
FORM PTO-1449			ATTY. DOCKS NO 30727.001 P1	- 1	AL NO. 18,501
LIST OF PATENTS AND OTHER IT INFORMATION DISCLOSU		APPLICANT: METABASIS THERAPEUTICS, INC.			
(Use several sheets if	necessary)		FILING DATE: March 5, 1999	GROI 160	UP:
OIPE	•			"	·CA
FFR 2 5 2007 50	,			M4	ROSIVE A
	U.S. PATER	NT DOC	UMENTS	ECH CENT	7 7000
EXAMINER INITIAL DOCUMENT NUMBER	DATE .		NAME	CLASS C	FILING DATE

Bielefeld, et al.

Biller, et al.

Gruber, et al.

01/23/62

10/20/92

8/19/97

3,018,302

5,157,027

5,658,889

•			FOREIGN	PATENT DOCUMENTS				
EXAMINER				CALIFERN	C14CC	SUB	TRANS	ATION NO
INITIAL		DOCUMENT NUMBER	DATE	EP (and English language	CLASS	1 4485	165	, NO
TUM	AD	0 002 062 A1	30.05.79	-Abstract)				
TU	AE	0 072 531 A1	23.02.83	EP-(and English tanguage -Abstract)				
Cr	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)				
	AG	0 180 276 A1	28.12.88	EP				
	АН	0 261 283 A1	22.09.86	EP				
	Al	0 161 955 A1	21.11.85	EPO				
	AJ	0 338 372 A2	25.10.89	EPO				
	AK	0 353 692 A2	07.02.90	EPO				
	AL	0 481 214 B1	22.04.92	EPO				
	AM	492 738	30.06.70	CH (and English language Abstract)				
V	AN	987,378	17.09.70	UK				

Many Mull	1/8/02
EXAMINER: Initial if reference is considered, whether or hine through citation if not in conformance and not consider communication to applicant	not citation is in conformance with MPEP 609; Draw red. Include a copy of this form with next

DATE CONSIDERED:

FORM PTO-1449

list of patents and other items for applicant's Information disclosure statement

(Use several sherical decement)

ATTY. DOCKET NO. 30727.00 PIP1 applicant:

serial ho. 09/518,501

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999

Group: 1814

				راً ا					۰۷		·
				FÖRLEIGN	Patent documents	_		^	MA		VE
EXAMIN INITIA			DOCUMENT NUMBER	PLACE SATE	COUNTRY	a	ASS	ECE	SSAU	YES YES	ATTOWN OORO
	M	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)				- AND	A 1600	ATION OO PORTON
Ì		AP	96/01287	18.01.96	wo						
		AQ	97/03679	06.02.97	wo		<u> </u>				
		AR	98/09668	12.03.98	wo		<u> </u>				
		AS	98/39342	11.09.98	wo		L				
		AT	98/39343	11.09.98	wo		L				
		AU	98/39344	11.09.98	wo						

	OTHER DOCUMENTS (Including Author, Tide, Date, Pertinent Pages, etc.)							
N	ر AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997						
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopretidase (NEP, EC 3.4.24.11) Inhibitors, <u>J. Med. Chem.</u> 37: 498-511 (1994)						
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dloxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dloxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)						
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]l-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:488-495 (1995)						
V	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)						

EXAMINER: Examiner	Marces CM CS	19	DATE CONSIDERED:	gov				
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant								

•				. Colors				
FORM PT	ചന്ദകര ഇം	ATHADILIQUA EMETITI QENTO ONA 2004	ATTY. DOCKET NO. 30727.001 IP1 APPLICANT:	Serial No. 09/518,501				
(C) (C)	ROIM	Mation disclosure statement 5 200 2	METABASIS THERA	APEUTICS/VOC.				
		so several sheets if necessary)	Films Date: March 5, 1999	GROUP: CEN				
		· AND FREE		100 ga "Oz				
<u> </u>	OTH	er documents (Including Author, Ti	de, Date, Pertinent	Pages, escripto				
W	BA	Farquhar, et al., "Synthesis and Biologica oxazaphosphorinan-2-yl)-ß-D-arabinosyl] dioxazaphosphorinan-2-yl)-ß-D-arabinosyl[ß-D-Arabinofuranosyl]adenine 5'-Monop (1985)	adenine and 9-[5'-(2-0 yl]adenine: Potential N	0xo-1,3,2- eutral Precursors of 9-				
	88	Farquhar, et al., "Synthesis and Biologica Fluoro-2'-deoxyuridine 5'-Phosphate," J.	al Evaluation of Neutra Med. Chem. 26: 1153-	Derivatives of 5- 1158 (1983)				
	BC	Freed, et al., "Evidence For Acyloxymeth Deoxyribonucleotides as Extracellular So Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3	urces of Active 5'-Dec					
	BD	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864g/u.						
	BE	Hunston, et al., "Synthesis and Biological Derived from 2'-Deoxy-5-fluorouridine," 』	•	•				
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR,	<u>, Ser. Khim.</u> 6: 1201-12	248 (1987)				
	₿G	Lok, et al., "Neurotoxicity associated with treatment of chronic hepatitis B virus infe (1984)	adenine arabinoside i	nonophosphate in the				
	вн	Ludeman, et al., "Synthesis and Antitumo Preparation, Kinetic Studies, and Antican and Similar Compounds Related to the C Aldophosphamide," <u>J. Med Chem.</u> 29, 71	cer Screening of "Phe yclophosphamide Met	nyl ketophos phamide"				
	81	Meier, et al., "Cyclic Saligenyl Phosphotre didehydrothymidine (d4T) – A New Pro-N Lett. 7: 99-104 (1997)	· · · · · · · · · · · · · · · · · · ·					
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cy Thioinosinic Acid," J. Med. Chem. 22: 81		as Prodrugs of				
	8K	Neidlein, et al., "Mild Preparation of 1-Ber Application to the Synthesis of Cyclic Pho Amides," <u>Heterocycles</u> 35: 1185-1203 (19	osphonic Deisters and					

Examiner MMe Mr	DATE CONSIDERED:	
EXAMINER: Initial if reference is conside	ed, whether or not citation is in conformance with MPEP 609; Drad not considered. Include a copy of this form with next	æw

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMEND (Use several sheets if necessar)
	_	
	ОТН	IER DOCUMENTS (Including Anthon, Title, Date, Pertinent Pages (1)
ghe	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, 1979, Pages 53-61.
	ВМ	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1998)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	во	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
	BP ·	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin, 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1857-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
V	вт	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

	ш			والمراجع المراجع والمراجع والم					
Examiner Manager	$I_{l_{j}}$	DATE CONSIDERED:	41	0					
The state of the s	P		//						
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw									
line through citation if not in conformance and not considered. Include a copy of this form with next									
communication to applicant									

OUT. OR THE	lassifyps o plus elign (+) breide Urin Som → ↓ Lastinar Sto Popercent Rodustian Ant of 1888, no parcent one require	U.S. Patent and Yandama	PTO/SB/02A (69-60)	-
THE STATE	Substitute for form 1448A/PTO		Complato If Fineran	D _a
	Information disclosure	Application Number	09/518,501	
		Filing Doto	March 3, 2000	
	statement by applicant	First Hamed Inventor	Erion et al.	6.0
1		Group Art Unit	1824	
1	(use as many sheets as necessary)	Examinar Maraa	Mettonolo T. SA	\$

			U.S. PATENT DOCU		
Donather Indiator	CZO No.'	Name of the Control o	Cotal Constitution of Approximate	Octo of Production of Cities Consument MIS-OD-YYYY	Popos, Galeron, Usan, Wilmo Reforms Panangus er Amusus Brussa Aspect
920		6,054,587	Reddy et al.	04/25/00	•
		6,110,903	Kasibhatla et al.	08/29/00	
		6,284,748	Dang et al.	09/04/01	
		6,294,672	Reddy et al.	09/25/01	
		6,312,662	Erion et al.	11/06/01	
		6,399,782	Kasibhatla et al.	06/04/02	
147		6,489,476	Dang et al.	12/03/02	
					

Atterney Deciet Number | 45199.00013.RCE (CIP1)

	FOREIGN PATENT DOCUMENTS										
Exeminer Initials	City 24	Office	Foreign Patent Doo Number	pravni) IER (192. A.	Name of Potenting or Applicant of Cited Document	Octa of Publication of Cited Decement MM-00-YYYY	Pojin, Celanci, Lina, Vileno Delivera Pomijin er Deliveri Rijano Agran	70			
								\bigcap			
لـــــا	,	<u>لــــــــــــــــــــــــــــــــــــ</u>									

	non patent literature documents										
Encirchae Initicto											
			•								

				/		
Examiner Signature	10m	Meller	Date . Considered	4/10	6/04	
	, , ,	ا مار م			7	

"EVAINTER: tribil il reterence considered, whother by not faintien to in contemence with SIPEP 800. (Arew Una Curough climition to not in contemence end misconsidered, traduct copy of this form with next descrimentation to applicant.

*Unique eithien designation number. * See diseited tilinée of U.S. Patent Desuments. * Enter Celeo Unit bound the descument, by the bro-toliar code (AUPO Seenderd ST.3). * For Japanese potent decuments, the indication of the year of the origin of the Engage mast present and present to code manager of the potent document. * Rind of decument by the opprepriate symbols on indicated on the decument under WIPO Standard ST, 10 if possible. * Applicant to to place or check mech here if English Engages Translation to attached.

Burtan How Statement. This form is costimated to take 2.0 frown to complete. Time will very depending upon the needed of the individual case. Any comments on the amount of time you are required to complete this form should be can to the Chief information Chief. U.S. Patent and Tradement Chief. Whathington, OC 20231. BO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Applicant Commissionar for Potentia, Whathington, OC 20231.

. BOILIDIVAAMIMITOAAI

Sheet

Please type a plus sign (+) traids this box > +

CATENT

PTO/SB/GBA (08-09)
to type a plus sign (+) tripide this box → +

Approved for use through 10/31/2002. OLAB G851-0931

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many aheata as necessary)

Sheet 01

Complete if Kn. wn							
Application Number	09/518,501	_					
Filing Date	March 3, 2000						
First Named Inventor	Erion et al.						
Group Art Unit	1624	_					
Examiner Name	T. McKenzie						
Attorney Docket Number	45198.00013.RCE						

Examiner	Cite	U.S. Patent (Document	Name of Patentes or Applicant	Date of Publication of	Pages, Columns, Lines,
înitiate"	Ma.	Mugger .	(Code)	of Cited Document	Cited Document MM-OD-YYYY	Where Relevant PASsigns or Relevant Rigarya Appear
	 	<u> </u>		·		
	1					•
•						
						•
			ليا			

					ATENT DOCUMEN	TS		
Examiner City Initials No.	Foreign Patent Do			Name of Patentes or	Date of Publication of	Pages, Colours, Line, Where Relevant	T	
		Office	Number*	Kind Cold () Sures)	Applicant of Clini Document	Cited Document MM-DD-YYYY	White Referent Primiting or Referent Figures Appear	7*
							-	<u> </u>
		ـــــا						<u> </u>
		1				1		L

NON PATENT LITERATURE DOCUMENTS								
Extendiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the erlicle (when appropriate), title of the item (book, magazine, journal, sortel, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	10					
N		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5- fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).						
N		LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thloethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).						

\sim		/ /	
Examiner Signature Om 16	Date Considered	4/16/6	4
"EXAMINER: Initial If reference considered, whether or not citation is in a	conformance with MPEP 60	9. Oraw the through chatton to	in conformant

'Unique citation designation number. ¹ See ettached fonds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check must here if English tanguage Translation is ettached.

Burden Hour Statement: This term is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this term should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Pissen type o plus olgn (+) inside this box 👈 💠

阳 27

STEP OF THE PERSON NAMED IN

PTO/SB/08A (08-60)

032465.00013.RCE (CIP1)

a type o plus olign (+) Institute this box -> + Approved for use Unrough 10/31/2022, DMB 6831-6031
U.S. Polish and Tractement Officer: U.S. DEPARTMENT OF COMMERCE
Under the Papercent Reduction Act of 1885, no parcers are required to respend to a coefficient of information unclassed action of valid CMB contact during Substitute for form 1448A/PTO Complete If Known Application Number Filing Date nformation disclosure 09/518,501 March 3, 2000 statement by applicant First Named Invantor Erion ot al. Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** T. McKenzie Sheet of

Alterney Doctet Number

			U.S. PATENT DOCU	MENTS	
Examinar Initiato*	Çile No.'	U.S. Patent Document Number tom Cont Universe	Mains of Patinties or Applicant of Clied Desymant	Octo of Publication of Clied Decument Mich-DO-YYYY	Popus, Calusto, Linos, Wilcoto Robertos Popusgon er Redenad Figuros Appore

				FOREIGN P.	ATENT DÓCUMEN	TS		
Exeminer Initials	Cite No.1	ours,	Foreign Patent Dos Number ⁴	Filment Kird Coth (g/ krown)	, Name of Possisso er Applicant of Cited Constant	Octs of Publication of Citol Decement MM-DD-YYYY	Project, Catherine, Librar, Whose Reference Prosection or Reference	
							Ryco Ages .	F

	===		
	<u> </u>	(NON PATENT LITERATURE DOCUMENTS .	
Excurrincy/ Initiato	Cilo No.	Include name of the eather (In CAPITAL LETTERS), title of the entitle (when appropriate), title of the liam (book, megazine, journal, north), symposium, cetalog, etc.), dese, page(s), volume-base number(s), publisher, city under country where published.	7*
81	•	Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," Tetrahedron, 49(28):6123-6194 (1993).	Î
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," <u>J. Med. Chem.</u> , 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," <u>J. Chem. Soc., Perk. Trans.</u> 1, (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
U		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examinar Date Signature Considered

"EXCLAIMER: Initial is extension considered, whether or not distant to in conformance with MPEP 600. Drown strough chatton to not in conformance and not considered, include copy of this form with next communication to explicant.

Busten Hour Siziement: This ferm is estimated to take 2.0 hours to compete. Time will very depending upon the needs of the Individual case. Any comments on the armount of time you are required to complete this form about the sent to the Chief Internation Officer, U.S. Potent and Tradement Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[&]quot;Unique citation designation number. " See attached Kinds of U.S. Patent Documents." Enter Calco that bossed the document, by the two-latter code (AVPO Standard ST.3). " For Japanese potent documents, the indication of the year of the religin of the Emperer must precede the codel number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if passible. "Applicant is to place a drack mark have it English tanguage Translation is established.

EXTERN 8

(use as many sheets as necessary)

œf

PTO/SB/BRA (08-08)
So type o pius cign (+) indide this bout +

Aspected for the District Total 1/2002. Colds 6851-6931

U.S. Patent and Treatenant Color: U.S. OEPARTIMENT OF COMMERCE

United the Paperson Reduction Act of 1889, no particular total particular of behaviors of content for the content of the

Y. McKenzie

032485.00013.RCE (CIP1)

Substitute for form 1448A/PTO Complete If Known Application Number information disclosure 09/318,501 Filing Oato March 3, 2000 statement by applicant First Namod Inventor Erton et al. Group Art Unit 1826

Examiner Name

Attorney Dectet Number

ا	-	·	non patent literature documents	
	ndror ds	Cito No.	include norms of the outbur (in CAPITAL LETTERS), time of the criticis (colors appropriate), time of the item (been, megazine, javanet, each), cympactum, catalog, cita), dato, pages(o), votume-bous number(s), publisher, ally Onder country chara published.	T°
¥	1	<u> </u>	Phis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic a- acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro. J. Pharm. Sci.</u> , 4:49-59 (1996).	
			Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from t- Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	
			Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>IACS</u> , 79:430-436 (1957).	
			Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).	
•		•	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
			Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med.</u> Chem., 29:716-727 (1986).	
	·		McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
			Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977).	
			Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," L. Am. Chem. Soc., 112:6936-3942 (1990).	
Y			Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," <u>Tetrahedron</u> , 38(3):761-764 (1997).	

Date Staniature Considered

*EXAMINER: Indicated the state of the state

Burden Hour Statement: This farm is estimated to take 3.0 hours to complete. Time will vary depending upon the needs of the individual cose. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Petent and Tradements Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents, Washington, DC 20231.

¹ Unique disting designation number. 2 See elisabed Kinds of U.S. Patent Documento. 2 Enter Office that located the document, by the translater code (MPO Standard ST.3). 2 For Japanese patent documents, the indicated of the year of the reign of the Emperor must precede the early number of the patent document. 3 Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 10 II possible. 3 Applicant is to place a check mark here if English Englage Translation is attached.

PTO/SB/88A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid CMB control number

PE	10	Substitute for form 1449A	PTO		Co	mpleta If Known
)	7)	NFORMATION	DISC	CI OSURE	Application Number	09/518,501
•			_	=	Filing Date	March 3, 2000
EB 5	5	TATEMENT BY	r Ar	PLICANI	First Named Inventor	Erion et al.
,					Group Art Unit	1624 -
2		(use as mahy	sheels	as necessary)	Examinar Name	T. McKenzie
PATEM &	Definee!	3	of	3	Attorney Docket Number	032465.00013.RCE (CIP1)

•		NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats	Cita No.1	Include name of the suffer (in CAPITAL LETTERS), title of the stricte (when appropriate), title of the item (book, magazine, journal, sental, sympostum, catalog, etc.), date, page(s), volume-issue number(s), publisher, only and/or country where published.	T*
81		Starrett, Jr. et al., "Synthesis, Oral Bloavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," <u>J. Chem. Soc., Perk. Trans. 1</u> , (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," <u>Biochem. Pharm.</u> , 45(8):1685-1694 (1993).	
1		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4- Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Examiner Date Signature Considered

*EXAMPLER: Initial if reference considered, whether or not pletton is in conformance with MPEP 609. Draw and through cratton is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This term is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, 'U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}Unique distion dealgration number. * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English tanguage Transfellon is attached.

			01.61				Page 1 of 3
			JUN 2 8 2005 E	ATTY. DOCKET NO. 2358.0010002/RWE	• 1 -	APPLICATION NO. 19/518,501	
	F	FORM PTO-144	704 6	FIRST NAMED INVENTED Erlon et al.			
INFO	RMATION	DISCLOSURE	MATEMENT 18	FILING DATE		RT UNIT	
			U.S. PA	March 3, 2000 TENT DOCUMENTS		624	
EXAMINER		DOCUMENT		1		CLID CLASS	EII ING DATE
INITIAL	AA1	NUMBER 3,404,178	DATE 10/01/1968	Roy, C.H.	CLASS	SUB-CLASS	FILING DATE 10/07/1965
7	AB1	4,621,077	11/04/1986	Rosini et al.		 	06/08/1984
	AC1	4,659,825	04/21/1987	Holy et al.			01/06/1984
	AD1	4,705,651	11/10/1987	Staibano			10/11/1985
	AE1	4,724,232	02/09/1988	Rideout et al.	-		09/17/1985
	AF1	4,724,233	02/09/1988	De Clercq et al.			04/21/1986
	AG1	4,777,163	10/11/1988	Bosies et al.			07/24/1987
	AH1	4,808,716	02/28/1989	Holy et al.		++	04/25/1986
	Al1	4,861,759	08/29/1989	Mitsuya et el.			08/11/1987
	AJ1	4,879,277	11/07/1989	Mitsuya et al.			08/11/1987
	AK1	4,882,142	11/21/1989	Simon et al.			12/19/1988
			FOREIGN I	PATENT DOCUMEN	TS		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP	 					Yes No
		OTHER	(Including Autho	or, Title, Date, Pertin	ent Pages, etc)	
	AR						
.•							
							-
	AS						
	AT					,	
_	AT					1 1	: : 5 : • •
EXAMINER	M.	1/1/1/	ees		DATE	ONSIDERED	
EXAMINER: H	tal If reserve	nge considered, wh	ether or hot diation is	In conformance with MPE	P 609. Drawline th	rough oflation if no	t in conformance

OIPE		
0		
JUN 2 8 2005 5	ATTY, DOCKET NO. -2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
FORM PTO-1	FIRST NAMED INVENTOR Erion et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	March 3, 2000	1624

	U.S. PATENT DOCUMENTS											
EXAMIN INITIAL	ER		DOCL	JMENT SER	DATE	NAME	c	LASS		SUB-CL	ss	FILING DATE
4	1	AA2	4,898	724	02/06/1990	Simon et al.						05/14/1987
		AB2	4,939,	130	07/03/1990	Jaeggi et el.						02/27/1989
		AC2	5,034,	394	07/23/1991	Daluge						12/22/1989
		AD2	5,047,	533	09/10/1991	Reist et al.						01/22/1990
		AE2	5,089,	500	02/18/1992	Daluge						05/08/1991
		AF2	5,153,	183	10/06/1992	Kawabe et al.					•	05/06/1991
·····		AG2	5,210,	085	05/11/1993	Liotta et al.						02/22/1991
		AH2	5,240,	946	08/31/1993	Kinney et al.		\neg				04/29/1992
		Al2	5,246,	937	09/21/1993	Hamden et al.						01/22/1992
		AJ2	5,366,	965	11/22/1994	Strein	:					01/29/1993
0		AK2	5,480,	875	01/02/1996	Isomura et al.						371 Date: 12/21/1994
					FOREIGI	N PATENT DOCUM	MENTS					1122111004
EXAMIN INITIAL	ER			CUMENT IBER	DATE	COUNTRY		CLAS	s	SUB-CLA	ss	TRANSLATION
		AL									_	Yes No
		AM										Ye: No
		AN		•								Ye:
		AO										Ye:
		AP					_					Yes No
				OTHER (I	ncluding Aut	thor, Title, Date, Pe	ertinent Pag	305, 0	tc.)			
		AR										,
		AS					·					
		AT		/								/
EXAMINI		37/		The K	en .			1		ONSTRE		67
EXAMINE and not co	R: Initia	al il refere	nce co	sidered whet	her of not citation th next communic	is in conformance with ation to Applicant.	MPEP 609. Dr	aw line	thro	ugh distion	if not	In conformance

Page 2 of 3

•	OIPE		
	(1)		Page 3 of 3
	JUN 2 8 2005 6	ATTY. DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
FORM PTO-1449		FIRST NAMED INVENTOR	
INFORMATION DISCLOSURE	STAPPMEND NY	Erion et al. FILING DATE	ART UNIT
· ·		March 3, 2000	1624

					Ų.S	S. PA	TENT DOCUME	ENTS					
EXAMINE	ER		DOCUM										
INITIAL			NUMBE		DATE		NAME		CLAS	<u> </u>	SUB-C	LASS	FILING DATE
1	ノ	AA3	5,532,22	?5	07/02/1996		Reist et al.						07/31/1992
		AB3	5,583,12	22	12/10/1996		Benedict et al.			1			12/08/1985
		AC3	5,663,15	59	09/02/1997		Starrett, Jr. et al.	-					10/11/1994
		AD3	5,681,59	90	10/28/1997		Bechard et al.						371 Date: 07/26/1995
		AE3	5,721,21	9	02/24/1998		Ingall <i>et al</i> .						08/09/1995
		AF3	5,814,63		09/29/1998		Liotta et el.						02/16/1993
		AG3	5,840,71	16	11/24/1998		Ubasawa et al.		1				01/17/1997
		AH3	5,869,46	57	02/09/1999		Holy et al.		1				03/28/1995
V		Al3	5,914,33	31	06/22/1999		Liotta et el.		1				06/07/1995
		AJ			-		· · · · · · · · · · · · · · · · · · ·					-	
		AK .											
					FORE	IGN	PATENT DOCU	MENTS					
EXAMINE INITIAL	ER		DOCU		DATE		COUNTRY	\	CLAS	ss	SUB-C	ASS	TRANSLATION"
	$\overline{\ }$	AL)					Yes No
		AM											Yes No
		AN											Yes No
													Yes
		AO											No Yes
		AP	4	THER!	Including	Auth.	or, Title, Date, f	Portingat D	2000			<u></u> l	No
			, 	JINEK (including /	Autik	or, rille, Dale, r	erunent P	ayes,	etc.)			
		AR											
		AS								İ		•	:
		AT .			10						,	/	•••
EXAMINE	R	5	. //	10/		_			D	ATE	ZO/SID	ERED	_
EXAMINER and not cor	R: India	il if reler d. Includ	exce consider copy of	dered, whe	ther or not cita th next comm	ation is unicati	In conformance wit on to Applicant.	h MPEP 609.	Draw lir	e three	ugh diati	on if not	in conformance

403868_3.DOC

SKGF Rev. 12/03/03



Sheet 1 of 12

	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)
_		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages
-ten	A1	3,796,700	03/12/1974	Yoshioka et al.	all
	A2	4,255,566	03/10/1981	Carrico et al.	all
	A3	4,318,982	03/09/1982	Homby et al.	all
	A4	4,340,668	07/20/1982	Hornby et al.	all
	A5	4,376,165	03/08/1983	Homby et al.	all
	A6	4,447,529	05/08/1984	Greenquist et al.	all
	A7	4,804,655	02/14/1989	Müller et al.	all
	A8	5,204,355	04/20/1993	Zsadon et al.	all
	A9	5,212,304	05/18/1993	Fung et al.	all
	A10	5,258,538	11/02/1993	Fung et al.	all
	A11	6,117,873	09/12/2000	Acklin et al.	all
. /	A12	6,752,981 B1	06/22/2004	Erion et al.	all
W	A13	6,756,360 B1	06/29/2004	Erion et al.	all

FOREIGN PATENT DOCUMENTS

		1 011	FIGHTALENI D	OOUNEITIO		
Examiner Initials*	Cite No.	Document (Cty code-number-kind)	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages	T
41	B1	WO 91/19721 A1	12/26/1991	Glazier, Arnold	all	
M	B2	WO 97/22614 A1	06/26/1997	Chiroscience Ltd.	all	
N	В3	WO 01/39724 A2	06/07/2001	Regents of Univ. of Calif.	all	
					all	
·						
, 					<u> </u>	
	· · · · · ·					-

Examiner Signature Considered 3/1/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 2 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	
	C1	ALARCON, R.A., "Studies on the In Vivo Formation of Acrolein: 3-Hydroxy-	
atta		propylmercapturic Acid as an Index of Cyclophosphamide (NSC-26271) Activation,"	
$ $ $ $ $ $	1'	Cancer Treatment Reports 60(4), 327-335, U.S. National Cancer Institute (1976).	<u></u>
	C2	ALEXANDER, P. et al., "Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as	
1 1		Potential Prodrugs," Collect. Czech. Chem. Commun. 59, 1853-1869, Nakladatelstvi	
	•	Ceskoslovenski Akademie Ved. (1994).	
	C3	AMIN, D. et al., "1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic Acid as	
1 1		a Potent Inhibitor of Squalene Synthase," ArzneimForsch/Drug Res. 46(8), 759-762,	
		Editio Cantor (1996).	
	C4	ANDERSON, L.W. et al., "Cyclophosphamide and 4-Hydroxycyclophosphamide/	
		Aldophosphamide Kinetics in Patients Receiving High-Dose Cyclophosphamide	
		Chemotherapy," Clinical Cancer Research 2, 1481-1487, American Association for	
		Cancer Research (1996).	
	C5	ANNAERT, P. et al., "Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-	
		Ester Prodrug of 9-(2-Phosphonylmethoxyethyl) Adenine in an In Vitro Cell Culture	i
		System of the Intestinal Mucosa (Caco-2)," Pharm. Res. 14(4), 492-496, Plenum	
		Publishing Corporation (1997).	
	C6	ATIQ, O.T. et al., "Treatment of Unresectable Primary Liver Cancer with Intrahepatic	
1		Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," Cancer 69(4), 920-	
	ļ	924, American Cancer Society (1992).	
	C7	AUBERSON, Y.P. et al., "N-Phosphonoalkyl-5-Aminomethylquinoxaline-2,3-Diones: In	
1		Vivo Active AMPA and NMDA-(Glycine) Antagonists," Bioorg. Med. Chem. Lett. 9, 249-	
	- <u>-</u> -	254, Elsevier Science Ltd. (January 1999).	ļ
1	C8	BAKER, M.A. et al., "Microtiter Plate Assay for the Measurement of Glutathione and	
1 1	-	Glutathione Disulfide in Large Numbers of Biological Samples," Anal. Biochem. 190, 360-	
 	-	365, Academic Press, Inc. (1990).	
	C9	BALTHAZOR, T.M. et al., "Nickel-Catalyzed Arbuzov Reaction: Mechanistic	
	1	Observations," J. Org. Chem. 45, 5425-5426, American Chemical Society (1980).	
	C10	BEDFORD, S.B. et al., "Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent	
		Combretastatin A4," Bioorg. Med. Chem. Lett. 6(2), 157-160, Elsevier Science Ltd.	
	<u> </u>	(1996).	

	1 116		
Examiner Signature	Melke	Date Considered 3/1/06	
	()		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 3 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	
C11 Beilstein Registry Number 3635189, Beilstein Institut zur Foerderung der Chemischer Wissenschaften (1991).		Beilstein Registry Number 3635189, Beilstein Institut zur Foerderung der Chemischen	
	C12	BENTRUDE, W.G. et al., "Stereo- and Regiochemistries of the Oxidations of 2-Methoxy-5-tert-butyl-1,3,2-dioxaphosphorinanes and the Cyclic Methyl 3'5'-Phosphite of Thymidine by H ₂ O/I ₂ and O ₂ /AIBN to P-Chiral Phosphates. ¹⁷ O NMR Assignment of Phosphorus Configuration to the Diasteromeric Thymidine Cyclic Methyl 3'5'-Monophosphates," <i>J. Am. Chem. Soc.</i> 111, 3981-3987, American Chemical Society (1989).	
	C13	BERRY, M.N. et al., "High-Yield Preparation of Isolated Rat Liver Parenchymal Cells," J. of Cell Biology 43, 506-520, Rockefeller University Press (1969).	
	C14	BESPALOV, A. et al., "Prolongation of Morphine Analgesia by Competitive NMDA Receptor Antagonist D-CPPene (SDZ EAA 494) in Rats," <i>Eur. J. Pharmacol.</i> 351, 299-305, Elsevier Science B.V. (June 1998).	
	C15	BIJSTERBOSCH, M.K. et al., "Disposition of the Acyclic Nucleoside Phosphonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxyproply)Adenine," <i>Antimicrobial Agents and Chemotherapy</i> 42, 1146-1150, American Society for Microbiology (May 1998).	
	C16	BIRD, J. et al., "Synthesis of Novel N-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," J. Med. Chem. 37, 158-169, American Chemical Society (1994).	
	C17	BODDY, A.V. et al., "Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide," <i>J. National Cancer Institute</i> 84(22), 744-748, Oxford University Press (1992).	
	C18	BORCH, R.F. et al., "Synthesis, Activation and Cytotoxicity of Aldophosphamide Analogues," <i>J. Med. Chem.</i> 34, 3052-3058, American Chemical Society (1991).	
	C19	BORCH, R.F. et al., "Synthesis and Antitumor Properties of Activated Cyclophosphamide Analogues," <i>J. Med. Chem.</i> 34, 3044-3052, American Chemical Society (1991).	
	C20	BOYD, V.L. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 3. Preparation, Molecular Structure Determination, and Anticancer Screening of Racemic cis- and trans-4-Phenylcyclophosphamide," J. Med. Chem. 23, 372-375, American Chemical Society (1980).	
d	C21	BRAIN, E.G.C. et al., "Modulation of P450-Dependent Ifosfamide Pharmacokinetics: a Better Understanding of Drug Activation In Vivo," <i>British J. of Cancer</i> 77(11), 1768-1776, Cancer Research Campaign (June 1998).	

Examiner		1.//-	Date	/10	100
Signature	/ Vem M	Ch	Considered 3	1161	<u> </u>

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 4 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner	Cite		TT
Initials*	No.	Description	'
ii ii lais	C22	BRENNA, O. et al., "Affinity-Chromatography Purification of Alkaline Phosphatase from	
	C22	Calf Intestine," <i>Biochem. J.</i> 151, 291-296, Portland Press on behalf of The Biochemical	1
Th	i	1	
	000	Society (1975).	
	C23	BRILL, T.B. et al., "Arbuzov-like Dealkylation Reactions of Transition-Metal-Phosphite	
		Complexes," Chem. Rev. 84, 577-585, American Chemical Society (1984).	
	C24	BROCK, N. et al., "Acrolein, the Causative Factor of Urotoxic Side-effects of	
		Cyclophosphamide, Ifosfamide, Trofosfamide and Sufosfamide" Arzneimittel Forschung	
		Drug Research 29(4), 659-661, Editio Cantor (1979).	
	C25	CAMPAGNE, JM. et al., "Synthesis of Mixed Phosphonate Diester Analogues of	
		Dipeptides using BOP or PyBOP Reagents," Tetrahedron Lett. 34(42), 6743-6744,	
		Pergamon Press Ltd. (1993).	
	C26	CAMPBELL, D.A., "The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu	
1		Reaction," J. Org. Chem. 57, 6331-6335, American Chemical Society (1992).	
	C27	CASARA, P.J. et al., "Synthesis of Acid Stable 5'-O-Fluoromethyl Phosphonates of	
		Nucleosides. Evaluation as Inhibitors of Reverse Transcriptase," Bioorg. Med. Chem.	1
		Lett. 2(2), 145-148, Pergamon Press plc. (1992).	
	C28	CASTEEL, D.A. et al., "Steric and Electronic Effects in the Aryl Phosphate to	
		Arylphosphonate Rearrangement," Synthesis, 691-693, Sendai Institute of Heterocyclic	
	}	Chemistry (1991).	
	C29	CHANG, T.K.H. et al., "Enhanced Cyclophosphamide and Ifosfamide Activation in	-
	023	Primary Human Hepatocyte Cultures: Response to Cytochrome P-450 Inducers and	
1		Autoinduction by Oxazaphosphorines," Cancer Research 57, 1946-1954, American	1
1		Association for Cancer Research (1997).	
	C30	CHEN, L. et al., "Intratumoral Activation and Enhanced Chemotherapeutic Effect of	
	C30		
		Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a	
		Combined Chemotherapy/Cancer Gene Therapy Strategy," Cancer Research 55, 581-	
	051	589, American Association for Cancer Research (1995).	-
	C31	CHEN, L. et al., "Sensitization of Human Breast Cancer Cells to Cyclophosphamide and	
		Ifosfamide by Transfer of a Liver Cytochrome P450 Gene," Cancer Research 56, 1331-	
		1340, American Association for Cancer Research (1996).	
\	C32	CLARK, L. et al., "Oxidative Metabolism of Cyclophosphamide: Identification of the	
		Hepatic Monooxygenase Catalysts of Drug Activation," Cancer Research 49, 2344-2350	
~		American Association for Cancer Research (1989).	1_

	\mathcal{L}	^ .			
Examiner Signature Dom Mc		Date Considered	ડ	/11	106
		7		,	7

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 5 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

	1 5	HOW PATERITERATORE DOCUMENTS	T = 1
Examine			T'
Initials*			
۸مه	C33	DAVIS, L. et al., "Effect of Withania somnifera on Cyclosphosphamide-induced	
9		Urotoxicity," Cancer Letters 148, 9-17, Elsevier Science Ireland Ltd. (January 2000).	
1	C34	DEARFIELD, K.L. et al., "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate	
1 1		Compounds in L5178Y Mouse Lymphoma Cells," Mutagenesis 4, 381-393, IRL Press,	
		Oxford (1989).	
\	C35	DELEVE, L.D. et al., "Cellular Target of Cyclophosphamide Toxicity in the Murine Liver:	
	}	Role of Glutathione and Site of Metabolic Activation," <i>Hepatology</i> 24(4), 830-837,	
		American Association for the Study of Liver Diseases (1996).	
	C36	DELOMBAERT, S. et al., "Pharmacological Profile of a Non-Peptidic Dual Inhibitor of	
		Neutral Endopeptidase 24.11 and Endothelin-Converting Enzyme," Biochem. Biophys.	
		Res. Commun. 204(1), 407-412, Academic Press, Inc. (1994).	
	C37	DESOS, P. et al., "Structure-Activity Relationships in a Series of 2(1H)-Quinolones	
		Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1H)-oxoquinoline-3-	
		phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with	
		Neuroprotective Properties," J. Med. Chem. 39, 197-206, American Chemical Society	
		(1996).	
	C38	DICKSON, J.K. et al., "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl)	
		Prodrugs of the a-Phosphonosulfonic Acid Moiety," J. Med. Chem. 39, 661-664, American	
		Chemical Society (1996).	
	C39	ENRIQUEZ, P.M. et al., "Conjugation of Adenine Arabinoside 5'-Monophosphate to	
		Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," <i>Bioconjugate Chem.</i>	
		6, 195-202, American Chemical Society (1995).	
	C40	ERION, M.D. et al., "Design, Synthesis, and Characterization of a Series of Cytochrome	
		P ₄₅₀ 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-	
		Based Drugs to the Liver," J. Am. Chem. Soc. 126, 5154-5163, American Chemical	
		Society (April 2004).	
	C41	ERION, M.D. et al., "Liver-Targeted Drug Delivery Using HepDirect Prodrugs," J. of	
		Pharmacology & Experimental Therapeutics 312(2), 554-560, The American Society for	-
		Pharmacology and Experimental Therapeutics (February 2005).	
	C42	FARQUHAR, D. et al., "Biologically-Cleavable Phosphate Protective Groups: 4-Acyloxy-	
	/\/ 1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates,"		
		Tetrahedron Lett. 36(5), 655-658, Elsevier Science Ltd. (1995).	1

Examiner	Wc. 1 Gio	Date	• / /
Signature / / Chy	140180	Considered	111/00

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 6 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

		HONT ATENT ETTERATORE BOOGNIERTO	T
Examiner	Cite	·	T
Initials*	No.	Description	<u> </u>
gri	C43	FIUME, L. et al., "Inhibition of Hepatitis B Virus Replication by Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin," <i>The Lancet</i> 13-15, Lancet Publishing Group (1988).	
	C44	FRAISER, L. et al., "Murine Strain Differences in Metabolism and Bladder Toxicity of Cyclophosphamide," <i>Toxicology</i> 75, 257-272, Elsevier Scientific Publishers (1992).	
	C45	GAO, Y. et al., "Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-A1," J. Org. Chem. 53, 4081-4084, American Chemical Society (1988).	
	C46	GILARD, V. et al., "Chemical Stability and Fate of the Cytostatic Drug Ifosfamide and Its N-Dechloroethylated Metabolities in Acidic Aqueous Solutions," <i>J. Med. Chem.</i> 42, 2542-2560, American Chemical Society (July 1999).	
	C47	GROEN, A.K. et al., "Intracellular Compartmentation and Control of Alanine Metabolism in Rat Liver Parenchymal Cells," Eur. J. Biochem. 122, 87-93, FEBS (1982).	
	C48	GUIDA, W.C. et al., "Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics," <i>J. Med. Chem.</i> 37, 1109-1114, American Chemical Society (1994).	
	C49	GURTOO, H.L. et al., "Role of Glutathione in the Metabolism-dependent Toxicity and Chemotherapy of Cyclophosphamide," Cancer Research 41, 3584-3591, American Association for Cancer Research (1981).	
	C50	GUSTIN, N.C. et al., "A Rapid, Sensitive Assay for Adenosine Deaminase," <i>Analytical Biochemistry</i> 71, 527-532, Academic Press, Inc. (1976).	
	C51	HAYAKAWA, Y. et al., "Benzimidazolium Triflate as an Efficient Promoter for Nucleotide Synthesis via the Phosphoramidite Method," <i>J. Org. Chem.</i> 61, 7996-7997, American Chemical Society (1996).	
	C52	HILTON, J., "Role of Aldehyde Dehydrogenase in Cyclophosphamide-resistant L1210 Leukemia," Cancer Research 44, 5156-5160, American Association for Cancer Research (1984).	
d	C53	HIRAYAMA, N. et al., "Structure and Conformation of a Novel Inhibitor of Angiotensin I Converting Enzyme - a Tripeptide Containing Phosphonic Acid," Int. J. Pept. Protein Res. 38, 20-24, Munksgaard International Publishers (1991).	

Examiner		1/1/////	Date	2/1/	~ (
Signature	10m	11/1/40	Considered	3/11/	2
	7 				

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 7 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	'
- Title	C54	JOUNAIDI, Y. et al., "Frequent, Moderate-Dose Cyclophosphamide Administration	
	"	Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer	į
W		Gene Therapy," Cancer Research 61, 4437-4444, American Association for Cancer	
1/		Research (June 2001).	
	C55	KACHEL, D.L. et al., "Cyclophosphamide-Induced Lung Toxicity: Mechanism of	
		Endothelial Cell Injury," J. Pharmacology and Experimental Therapeutics 268(1), 42-46,	
		The American Society for Pharmacology and Experimental Therapeutics (1994).	
	C56	KEENAN, R.E. et al., "Pathology Reevaluation of the Kociba et al. (1978) Bioassay of	
1	j	2,3,7,8-TCDD: Implications for Risk Assessment," J. Tox. Envir. Health 34, 279-296,	1
		Hemisphere Publishing Corporation (1991).	
	C57	KELLEY, J.L. et al., "[[(Guaninylalkyl)phosphinico] methyl] phosphonic Acids.	
		Multisubstrate Analogue Inhibitors of Human Erythrocyte Purine Nucleoside	
		Phosphorylase," J. Med. Chem. 38, 1005-1014, American Chemical Society (1995).	ļ
	C58	KHAMNEI, S. et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,"	
		J. Med. Chem. 39, 4109-4115, American Chemical Society (1996).	
	C59	KURIYAMA, S. et al., "Transient Cyclophosphamide Treatment Before Intraportal	
'	Readministration of an Adenoviral Vector can Induce Re-expression of the Original Gene Construct in Rat Liver," Gene Therapy 6, 749-757, Stockton Press (May 1999).		1
	000		
	C60	KWON, CH. et al., "Effects of N-Substitution on the Activation Mechanisms of 4-	
	•	Hydroxycyclophosphamide Analogues," <i>J. Med. Chem.</i> 32, 1491-1496, American Chemical Society (1989).	
	C61	LILO, B. et al., "Synthesis and Configurational Assignment of Bicyclic 'Preactivated'	
	COI	Analogues of Cyclophosphamide," <i>Tetrahedron Letters</i> 31(6), 887-890, Pergamon Press	
	ļ .	plc. (1990).	
 	C62	LOW, J.E. et al., "Conversion of 4-Hydroperoxycyclophosphamide and 4-	
	""	Hydroxycyclophosphamide to Phosphoramide Mustard and Acrolein Mediated by	
	ĺ	Bifunctional Catalysts," Cancer Research 42, 830-837, American Association for Cancer	
		Research (1982).	
	C63	LU, X. et al., "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with O,O-	
	}	Dialkyl Phosphonates," Synthesis 726-727, Academic Press (1987).	<u>L</u>
	C64	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogs.	
$ \Delta $		1. Benzo Annulated Cyclophosphamide and Related Systems," J. Med. Chem. 18(12),	
Ur .		1251-1253, American Chemical Society (1975).	1

		\mathcal{L}		
Examiner	1, 1	1 / 1/	Date	2//
Signature		Chr Wells	Considered	5/4/06

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPPP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 8 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

	1		T_T
Examiner	Cite	<u> </u>	T'
Initials*	No.	Description	ļ
	C65	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide	
	ŀ	Analogues. 2. Preparation, Hydrolytic Studies, and Anticancer Screening of 5-	
an		Bromocyclophosphamide, 3,5-Dehydrocyclophosphamide, and Related Systems," J.	
Ι,		Med. Chem. 22(2), 151-158, American Chemical Society (1979).	
7	C66	LUDEMAN, S.M. et al., "Synthesis of Reactive Metabolite-Analogues of	
/		Cyclophosphamide for Comparisons of NMR Kinetic Parameters and Anticancer	
1 1		Screening Data," Drugs Exptl. Clin. Res. XII 6/7, 527-532, Bioscience Ediprint Inc. (1986).	İ
	C67	MAY-MANKE, A. et al., "Investigation of the Major Human Hepatic Cytochrome P450	
] }		Involved in 4-Hydroxylation and N-dechloroethylation of Trofosfamide," Cancer	
		Chemother. Pharmacol. 44, 327-334, Springer-Verlag (August 1999).	
	C68	MAYNARD-FAURE, P. et al., "New Strategy for the Diastereoselective Synthesis of	
		Bicyclic 'Pre-activated' Analogues of Cyclophosphamide," Tetrahedron Letters 39, 2315-	.
	1	2318, Elsevier Science Ltd. (April 1998).	1
	C69	MCGUIGAN, C. et al., "Kinase Bypass: A New Strategy for Anti-HIV Drug Design,"	
		Bioorganic & Medicinal Chemistry Letters 3(6): 1207-1210, Pergamon Press Ltd. (1993).	
	C70	MEIER, C. et al., "ADA-Bypass by lipophilic Cyclo-Sal-ddAMP Pro-Nucleotides A second	
		Example of the Efficiency of the cycloSat-Concept," Bioorg. Med. Chem. Lett. 7(12),	
		1577-1582, Elsevier Science Ltd. (1997).	
	C71	MEIER, C. et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-	1
	• • •	didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," Bioorganic Med. Chem.	
		Lett. 7(2), 99-104, Elsevier Science Ltd. (1997).	
	C72	MEIJER, D.K.F. et al., "Covalent and Noncovalent Protein Binding of Drugs: Implications	
1 1	0,12	for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," <i>Pharm. Res.</i> 6(2), 105-	
	l	118, Plenum Publishing Corporation (1989).	
 	C73	MELVIN, L.S., "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," <i>Tetrahedron</i>	
	0/3	Lett. 22(35), 3375-3376, Pergamon Press Ltd. (1981).	
 	C74	MISIURA, K. et al., "Synthesis and Antitumor Activity of Analogues of Ifosfamide Modified	
1 /	0/4	in the N-(2-Chloroethyl) Group," <i>J. Med. Chem.</i> 31(1), 226-230, American Chemical	
1 /		Society (1988).	1
 	C75	MITCHELL, A.G. et al., "Bioreversible Protection for the Phospho Group: Bioactivation of	1
1 /	10/3	the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of]
	ĺ		
U.	[Methylphosphonate and Phosphonacetate," J. Chem. Soc. Perkin Trans. 1, 2345-2353,	1 1
<u>'</u>	L	Chemical Society, London (1992).	<u> </u>

Examiner Signature	Ton	Mest.	Date Considered	3/11/6	26
	(7			

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 9 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner	Cite		T
Initials*	No.	Description	
IIIIIais	C76	MITCHELL, J.R. et al., "Acetaminophen-Induced Hepatic Necrosis. IV. Protective Role of	
010	0/0	Glutathione," <i>J. Pharmacology and Experimental Therapeutics</i> 187(1), 211-217, The	
		Williams & Wilkins Co. (1973).	E
	C77	MITSUNOBU, O., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in	
/	011	Synthesis and Transformation of Natural Products," Synthesis 1-28, Georg Thieme	
/		Verlag (1981).	
 	C70	C78 MOORE, M.M. et al., "Comparison of Mutagenicity Results for Nine Compounds	
	0/8	Evaluated at the <i>hgprt</i> Locus in the Standard and Suspension CHO Assays,"	Ì
	070	Mutagenesis 6, 77-85, Oxford University Press (1991).	
	C79	MURRAY, G.I. et al., "Cytochrome P450 CYP3A in Human Renal Cell Cancer," British	
	000	Journal of Cancer 79, 1836-1842, Cancer Research Campaign (April 1999).	
	C80	MURRAY, G.I. et al., "Cytochrome P450 Expression is a Common Molecular Event in	1
		Soft Tissue Sarcomas," J. Pathology 171: 49-52, John Wiley & Sons, Ltd. (1993).	├ ──
	C81 NAGAMATSU, T. et al., "New Phosphorylating Agents for General Synthesis of Mixed		
	Phosphate Esters," Tetrahedron Lett. 28(21), 2375-2378, Pergamon Journals Ltd. (1987)		 -
1 \	C82	NAKAYAMA, K. et al., "A Highly Enantioselective Synthesis of Phosphate Triesters," J.	Ì
		Am. Chem. Soc. 112, 6936-6942, American Chemical Society (1990).	
C83 OGG, M.S. et al., "A Reporter Gene Assay to Assess the Molecular Mechanisms of			
Xenobiotic-dependent Induction of the Human CYP3A4 Gene in Vitro," Xenobiotica 29(3)			
		269-279, Taylor & Francis Ltd. (March 1999).	
	C84	OHASHI, K. et al., "Synthesis of Phosphonosphingoglycolipid Found in Marine Snail	
		Turbo Cornutus," Tetrahedron Lett. 29(10), 1189-1192, Pergamon Press plc. (1988).	
	C85	PETRAKIS, K.S. et al., "Palladium-Catalyzed Substitutions of Triflates Derived from	
		Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-	
}	•	(Diethoxyphosphinyl)phenylalanines and Diethyl Arylphosphonates," J. Am. Chem. Soc.	
		109, 2831-2833, American Chemical Society (1987).	ļ
	C86	PETTIT, G.R. et al., "Antineoplastic Agents 322. Synthesis of Combretastatin A-4	
	Prodrugs," Anti-Cancer Drug Design 10, 299-309, Oxford University Press (1995).		ļ
	C87	PITCHER, H.R., "Built-in Bypass," Nature 429, 39, Nature Publishing Group (May 2004).	
\sim	C88	RAMU, K. et al., "Acrolein Mercapturates: Synthesis, Characterization, and Assessment	
(_	-	of Their Role in the Bladder Toxicity of Cyclophosphamide," Chem. Res. Toxicol. 8, 515-	Ì
1	l	524, American Chemical Society (1995).	1

Examiner /		Date	2//
Signature V	nIIICIES	Considered	7/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 10 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

	1	HOIT FATEIT LITERATURE DOCUMENTS			
Examiner	Cite		T'		
Initials*	No.	Description	<u> </u>		
	C89	REDDY, M.R. et al., "Development of a Quantum Mechanics-Based Free-Energy			
an		Perturbation Method: Use in the Calculation of Relative Solvation Free Energies," J. Am.	•		
	000	Chem. Soc. 126, 6224-6225, American Chemical Society (May 2004).	ļ		
/	C90	REDMORE, D., "Phosphorus Derivatives of Nitrogen Heterocycles. 2.	ŀ		
Pyridinephosphonic Acid Derivatives," J. Org. Chem. 35(12), 4114-4117, American Chemical Society (1970)					
	C91	Chemical Society (1970).	<u> </u>		
1 1	Cal	REN, S. et al., "Inhibition of Human Aldehyde Dehydrogenase 1 by the 4-			
		Hydroxycyclophosphamide Degradation Product Acrolein," <i>Drug Metabolism and Disposition</i> 27(1), 133-137, The American Society for Pharmacology and Experimental			
'	ļ	Therapeutics (January 1999).			
	C92	REN, S. et al., "Pharmacokinetics of Cyclophosphamide and its Metabolites in Bone	-		
	UUL	Marrow Transplantation Patients," Clinical Pharmacology and Therapeutics 64(3), 289-			
		301, Mosby, Inc. (September 1998).			
	C93	ROY, P. et al., "Development of a Substrate-Activity Based Approach to Identify the	 		
		Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation			
		Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles," Drug			
		Metabolism and Disposition 27(6), 655-666, The American Society for Pharmacology and			
Experimental Therapeutics (June 1999).					
1	C94	SCHWARTZ, P.S. et al., "Cyclophosphamide Induces Caspase 9-Dependent Apoptosis			
in 9L Tumor Cells," <i>Molecular Pharmacology</i> 60(6), 1268-1279, The American Society for					
		Pharmacology and Experimental Therapeutics (December 2001).			
	C95	SHIH, YE. et al., "Studies on Potential Antitumor Agents (III). Synthesis of 4-			
		Arylcyclophosphamides," Heterocycles 9 (9): 1277-1285, Sendai Institute of Heterocyclic			
ļ	222	Chemistry (1978).			
į į	C96	SHIH, YE. et al., "Synthesis and Structure of 6-Phenylcyclophosphamides,"			
	007	Heterocycles 24(6), 1599-1603, Sendai Institute of Heterocyclic Chemistry (1986).	ļ		
	C97	SLADEK, N.E. et al., "Influence of Diuretics on Urinary General Base Catalytic Activity			
		and Cyclophosphamide-Induced Bladder Toxicity," Cancer Treatment Reports 66(11),			
	C98	1889-1900, U.S. National Cancer Institute (1982).	 		
	C30	SLADEK, N.E. et al., "Restoration of Sensitivity to Oxazaphosphorines by Inhibitors of Aldehyde Dehydrogenase Activity in Cultured Oxazaphosphorine-resistant L1210 and			
		Cross-Linking Agent-resistant P388 Cell Lines," Cancer Research 45, 1549-1555,			
		American Association for Cancer Research (1985).	1		
	C99	SPRINGATE, J. et al., "Toxicity of Ifosfamide and Its Metabolite Chloroacetaldehyde in	 		
_		Cultured Renal Tubule Cells," In Vitro Cell Dev. BiolAnimal 35, 314-317, Society for In			
	Vitro Biology (June 1999).				
Examine		Date 2 /. /	L		
Signature	_ \	Considered 3/11/06			
3		Considered 5 / 1/00			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 11 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	
-	C100	SUMIDA, A. et al., "Quantitative Analysis of Constitutive and Inducible CYPs mRNA	
an		Expression in the HepG2 Cell Line Using Reverse Transcription-Competitive PCR,"	
71,	_	Biochem. & Biophys. Res. Comm. 267, 756-760, Academic Press (January 2000).	
	C101	TURNER, J.A., "A General Approach to the Synthesis of 1,6-,1,7-, and 1,8-	
	Naphthyridines," J. Org. Chem. 55(15), 4744-4750, American Chemical Society (199		
	C102	VENOOK, A.P., "Treatment of Hepatocellular Carcinoma: Too Many Options?," J. Clin.	
		Oncol. 12(6), 1323-1334, Lippincott Williams & Wilkins (1994).	
1	C103	VO-QUANG, Y. et al., "(1-Amino-2-propenyl)phosphonic Acid, an Inhibitor of Alanine	
		Racemase and D-Alanine:D-Alanine Ligase," J. Med. Chem. 29(4), 579-581, American	
		Chemical Society (1986).	
ł i	C104	WAGNER, A. et al., "Direct Conversion of Tetrahydropyranylated Alcohols to the	-
		Corresponding Bromides," <i>Tetrahedron Letters</i> 30(5), 557-558, Pergamon Press plc.	
ļ		(1989).	
	C105	WALLACE, E.M. et al., "Design and Synthesis of Potent, Selective Inhibitors of	
		Endothelin-Converting Enzyme," J. Med. Chem. 41, 1513-1523, American Chemical	ľ
 	0.100	Society (April 1998).	ļ <u>.</u>
	C106	WALSH, E.N. et al., "Phenoxymethylphosphonic Acids and Phosphonic Acid Ion-	
		exchange Resins," J. Am. Chem. Soc. 78, 4455-4458, American Chemical Society	1
	0407	(1956).	
	C107	WATANABE, Y. et al., "Dibenzyl Phosphorofluoridate, A New Phosphorylating Agent,"	1
 	C400	Tetrahedron Letters 29(45), 5763-5764, Pergamon Press plc. (1988).	
	C108	WATKINS, P.B., "Noninvasive Tests of CYP3A Enzymes," <i>Pharmacogenetics</i> 4, 171-	ŀ
	C109	184, Chapman & Hall, London (1994). WEIBEL, M. et al., "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-Oxo-9H-Purin-9-	<u> </u>
	C 109	yl)Methyl]-Phenyl] Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine	
		Nucleoside Phosphorylase, on the Antiretroviral Activities of 2',3'-Dideoxyinosine	1
	:	Combined to Ribavirin in Mice," <i>Biochem. Pharmacol.</i> 48(2), 245-252, Elsevier Science	
		Ltd. (1994).	
	C110	WEINHARDT, K. et al., "Synthesis and Antidepressant Profiles of Phenyl-Substituted 2-	
	31.0	Amino- and 2-[(Alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines," J. Med Chem. 28,	
		694-698, American Chemical Society (1985).	! !
	C111	WILEMAN, T. et al., "Receptor-Mediated Endocytosis," <i>Biochem. J.</i> 232: 1-14, Portland	+ -
4		Press on behalf of the Biochemical Society, London (1985).	
		· · · · · · · · · · · · · · · · · · ·	

	A_AAA		
Examiner Signature	Melly	Date Considered 3 /	1/66

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 12 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

		NON FATENT EITERATURE DOCUMENTO	
Examiner	Cite	Description	T'
Initials*	No.	Description YIP, K.F. et al., "Use of High-Performance Liquid Chromatography in the Preparation of	
17	C112	Flavin Adenine Dinucleotide Analyte Conjugates," J. of Chromatography 326, 301-310,	
		Elsevier Science Publishers B.V., Amsterdam (1985).	
	C113		
	0113	Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," J.	
	-	Pharm. Exp. Ther. 288(3), 928-937, The American Society for Pharmacology and	1
		Experimental Therapeutics (March 1999).	
1/	C114		_
\mathcal{N}		Children," Drug Metabolism and Disposition 27(3), 417-421, The American Society for	
		Pharmacology and Experimental Therapeutics (March 1999).	
		·	T
			1
			
	Ì		
	, ·		
			· ————
Evamina		1/1 // Date 7 / /	

Examiner Signature	on Mc/9	Date Considered	11/06
			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.



Sheet 1 of 1

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner Initials*	Cite No.	Description	T
LUM	C115		
Cu	C116	Prodrugs Targeted against Cyclophosphamide-Resistant Tumor Cell Lines," <i>J. Med. Chem.</i> 47, 3843-3852 American Chemical Society (July 2004)	
pr	C117	Prosecution history of Dang, Q., et al., U.S. Application No. 09/389,698, filed September 3, 1999, now patented as 6,489,476 B1	
	C118		
	C119		
-	C120		
	C121		<u> </u>
	C122		
	C123		

		489176_1.DOC
Examiner (11/2/10-	Date //
Signature / Om	MOKE	Considered 1/1/66

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.



Sheet 1 of 2

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

U.S. PATENT DOCUMENTS

Examiner	Cite		Publication Date		Relevant
Initials*	No.	Document Number	(MM-DD-YYYY)	Name of Patentee or Applicant	Pages
	A14				
`	A15				
	A16				
-	A17		-		· · · · · · · · · · · · · · · · · · ·
	A18				
	A19				
	A20				
	A21	•			
	A22				
	A23				
· ····································	A24				
	A25		<u> </u>		
	A26				

FOREIGN PATENT DOCUMENTS

TOKEION ATEN DOCUMENTO									
Examiner Initials*	Cite No.			Name of Patentee or Applicant	Relevant Pages	T,			
TOM	B4	EP 0 072 987 A1	08-13-1982	Henkel Kommanditgesellschaft auf Aktien					
	B5								
	B6								
· · · · · · · · · · · · · · · · · · ·	B7								
	B8								
	B9					-			
	B10								
	B11								
	B12								
	B13								
	B14								

Examiner Signature Considered 3 /1/8_C

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.



Sheet 2 of 2

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite		T
Initials*	No.	Description	\perp
مد	C118	Delphion English-language abstract of European Patent Publication No. 0 072 987 A1,	
Ten		2 pages, accessed on October 20, 2005 at	
	C440	https://www.delphion.com/details?pn=EP00072987A1&s-FAMILY=1	
gr	C119	Unverified English-language translation of European Patent Publication No. 0 072 987 A1, 13 pages	
	C120		
	C121		
	CIZI		
	C122		
	C123		
	C124		
	C125		
	C126		
	C127		
Examine	r [Date 3/4/ac	

Examiner	}	11/	1/	Date	1	1. 7		
Signature	am	MC	Klerzo	- Considered	- イ/	/// <	56	
(,					 -	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.